We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+50.4%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.02B
AUM Growth
+$989M
Cap. Flow
+$219M
Cap. Flow %
7.24%
Top 10 Hldgs %
64.34%
Holding
48
New
8
Increased
9
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$62.3M
2
BHVN icon
Biohaven
BHVN
+$57.4M
3
JANX icon
Janux Therapeutics
JANX
+$42.1M
4
ADCT icon
ADC Therapeutics
ADCT
+$40.6M
5
IMVT icon
Immunovant
IMVT
+$37M

Top Sells

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$62.7M
2
UPB
Upstream Bio Inc
UPB
+$34.2M
3
IRON icon
Disc Medicine
IRON
+$30.7M
4
COGT icon
Cogent Biosciences
COGT
+$26.1M
5
ATXS
Astria Therapeutics
ATXS
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$9.89B
$959M 31.74%
7,111,596
– –
COGT icon
2
Cogent Biosciences
COGT
$6.02B
$208M 6.9%
5,868,162
-930,000
-14% -$26.1M
CGON icon
3
CG Oncology
CGON
$6.59B
$152M 5.04%
3,670,206
– –
TNGX icon
4
Tango Therapeutics
TNGX
$3.94B
$113M 3.74%
12,762,094
+4,225,898
+50% +$36.4M
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$107M 3.55%
4,286,480
+1,150,000
+37% +$29.1M
DYN icon
6
Dyne Therapeutics
DYN
$4.68B
$90.3M 2.99%
4,615,144
– –
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
$87.5M 2.89%
2,582,408
+946,133
+58% +$29.4M
TYRA icon
8
Tyra Biosciences
TYRA
$1.49B
$76.2M 2.52%
2,898,103
– –
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$3.87B
$75.4M 2.5%
6,243,812
– –
SVRA icon
10
Savara
SVRA
$1.08B
$74.5M 2.47%
12,362,205
– –
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$1.14B
$72.5M 2.4%
+4,622,151
New +$62.3M
OCUL icon
12
Ocular Therapeutix
OCUL
$2.28B
$69.7M 2.31%
5,740,231
-377,001
-6% -$4.58M
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.92B
$69.1M 2.29%
1,676,624
– –
EYPT icon
14
EyePoint Inc
EYPT
$386M
$65.3M 2.16%
3,572,335
– –
GPCR icon
15
Structure Therapeutics
GPCR
$3.38B
$64M 2.12%
920,857
-142,143
-13% -$5.8M
SYRE icon
16
Spyre Therapeutics
SYRE
$7.97B
$62.3M 2.06%
1,900,582
+800,000
+73% +$20.9M
FULC icon
17
Fulcrum Therapeutics
FULC
$294M
$59.4M 1.97%
5,250,000
– –
LQDA icon
18
Liquidia Corp
LQDA
$6.06B
$59M 1.95%
1,710,084
– –
BHVN icon
19
Biohaven
BHVN
$2.33B
$52.3M 1.73%
+4,631,317
New +$57.4M
IMVT icon
20
Immunovant
IMVT
$8.51B
$42.2M 1.4%
+1,660,933
New +$37M
KOD icon
21
Kodiak Sciences
KOD
$2.37B
$40.4M 1.34%
1,445,538
+300,000
+26% +$6.14M
ADCT icon
22
ADC Therapeutics
ADCT
$146M
$40.2M 1.33%
11,390,175
+10,000,000
+719% +$40.6M
LBRX
23
LB Pharmaceuticals
LBRX
$1.54B
$38.8M 1.29%
1,745,015
-1
-0% -$17
XNCR icon
24
Xencor
XNCR
$1.94B
$37.5M 1.24%
2,452,138
– –
RVMD icon
25
Revolution Medicines
RVMD
$44.6B
$34.8M 1.15%
436,473
– –
1
2

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q4 2025 Portfolio in Review

As of Q4 2025, TCG Crossover Management held 48 positions worth $3.02B, up 49% from $2.03B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

TCG Crossover Management deployed $219M of net new capital in Q4 2025, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was Monte Rosa Therapeutics: 4,622,151 shares worth $72.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Upstream Bio Inc, an estimated $34.2M trimmed.

  • TCG Crossover Management's largest Q4 2025 buy was Monte Rosa Therapeutics: 4,622,151 shares worth $72.5M.
  • TCG Crossover Management added most to ADC Therapeutics in Q4 2025, an estimated $40.6M increase.
  • TCG Crossover Management's biggest Q4 2025 reduction was Upstream Bio Inc, cutting an estimated $34.2M.
  • TCG Crossover Management fully exited Tourmaline Bio in Q4 2025, selling an estimated $62.7M.
  • TCG Crossover Management's ten largest holdings make up 64% of its $3.02B portfolio in Q4 2025.
  • TCG Crossover Management opened 8 new positions and closed 5 in Q4 2025.
  • TCG Crossover Management's portfolio value rose 49% quarter-over-quarter to $3.02B.

Based on TCG Crossover Management's 13F filing for Q4 2025, filed 17 Feb 2026.